Levosimendan-induced reduction in natriuretic peptide levels during the treatment of decompensated heart failure: Clinical implications - Reply

ÇAVUŞOĞLU Y., Tek M., Demirustu C.

INTERNATIONAL JOURNAL OF CARDIOLOGY, vol.128, no.1, pp.100-102, 2008 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Letter
  • Volume: 128 Issue: 1
  • Publication Date: 2008
  • Doi Number: 10.1016/j.ijcard.2008.03.005
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.100-102
  • Eskisehir Osmangazi University Affiliated: Yes


Although, the potential use of natriuretic peptide testing in treatment monitoring of heart failure remains to be fully clarified, levosimendan-induced reduction in natriuretic peptide levels has consistently been reported to be associated with favorable clinical, hemodynamic, anti-inflammatory and anti-apoptotic effects. Several studies demonstrated that not only is plasma natriuretic peptide level important predictor of long-term outcomes, but changes in natriuretic peptide levels during the treatment of heart failure are also associated with corresponding changes in morbidity and mortality. Re-analysis of the data from our previously published study suggested a greater percentage of NT-proBNP reduction at 48 h in patients who survived compared to those who died in both levosimendan (- 6 +/- 8% vs - 24 +/- 13%, respectively) and dobutamine (-32 +/- 8% vs+ 9 +/- 32%, respectively) treatment groups, although not statistically different. The changes in natriuretic peptide levels during therapy reflect short-term hemodynamic improvements and effectiveness of drug regimens, but also may have a role in predicting long-term outcomes. (C) 2008 Elsevier Ireland Ltd. All rights reserved.